OBJECTIVETo detect the DNA damage of the nurses occupationally exposed to anticancer drugs and to assess the exposure level using Comet assay.

METHODSSixteen nurses occupationally exposed to anticancer drugs were selected as exposure group, the average exposure period was 5.6 years, and the average exposure dose was to prepare 7.8 portions of anticancer drugs daily. Meanwhile, sixteen nurse students were selected as control group. The DNA migration of the peripheral lymphocytes of both groups was detected using comet assay.

RESULTSThe comet length was 46.27 microns in exposure group, which was significantly higher than that of control group (26.78 microns, P < 0.01). Also the percentage of long tailed nucleus (LTN) of exposure group was 64.83%, which was significantly higher than that of control group (4.87%, P < 0.01).

CONCLUSIONSThere was DNA damage in the nurses occupationally exposed to antineoplastic drugs.

Antineoplastic Agents ; adverse effects ; Drug-Related Side Effects and Adverse Reactions ; therapy ; Humans ; Neurotoxicity Syndromes ; therapy

Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitors (ICIs) are the most successful agents approved for multiple advanced malignancies. However, given the nature of the non-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related adverse events (irAEs) in almost all organs or systems. Up to 90% of patients who received ICIs combination therapy experienced irAEs, of which majority were low-grade toxicity. Cytotoxic lymphocyte antigen-4 and programmed cell death protein-1/programmed cell death ligand 1 inhibitors usually display distinct features of irAEs. In this review, the mechanisms of action of ICIs and how they may cause irAEs are described. Some unsolved challenges, however really engrossing issues, such as the association between irAEs and cancer treatment response, tumor response to irAEs therapy, and ICIs in challenging populations, are comprehensively summarized.
Antineoplastic Agents/adverse effects* ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy/adverse effects* ; Neoplasms/drug therapy*

Antineoplastic Agents/adverse effects* ; Head and Neck Neoplasms ; Humans ; Radiotherapy/adverse effects* ; Stomatitis/prevention & control*

No abstract available.
Antineoplastic Agents/*adverse effects ; Female ; Humans ; Indoles/*adverse effects ; Male ; Proteinuria/*chemically induced ; Pyrroles/*adverse effects ; Renal Insufficiency/*chemically induced

In recent years,great progress has been achieved in the application of immune checkpoint inhibitors (ICI) in tumor immunotherapy.However,a variety of adverse reactions induced by ICI have been reported.Despite the high overall incidence of adverse reactions caused by ICI,some adverse reactions,such as immune-related pancreatitis,are rare in clinical practice.In this paper,a case of immune-related pancreatitis after treatment of advanced gastric cancer with nivolumab was identified.We analyzed the cause,treatment,incidence,and risk factors of the adverse reaction,aiming to improve the clinical diagnosis,treatment,and safe medication of rare adverse reactions associated with ICI.
Humans ; Nivolumab/adverse effects* ; Immune Checkpoint Inhibitors/adverse effects* ; Antineoplastic Agents, Immunological/adverse effects* ; Pancreatitis/drug therapy* ; Stomach Neoplasms

Anti-Asthmatic Agents ; adverse effects ; therapeutic use ; Antineoplastic Agents ; adverse effects ; therapeutic use ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Lung Diseases ; chemically induced ; Pneumoconiosis ; drug therapy

Antineoplastic Agents ; adverse effects ; Humans ; Integrative Medicine ; Organoplatinum Compounds ; adverse effects ; Peripheral Nervous System Diseases ; chemically induced

Objective To assess the efficacy and safety of apatinib in the treatment of advanced colorectal cancer(CRC). Methods The clinical data of 16 CRC patients treated with apatinib after failure of prior lines of treatment were retrospectively analyzed in terms of objective response rate,disease control rate,progression-free survival,overall survival,adverse events,and prognostic factors. Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95%CI=1.57-4.42),and the median overall survival was 6.5 months(95%CI=4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival.Conclusion Apatinib may be effective in treating advanced CRC,with tolerable side effects.
Antineoplastic Agents ; adverse effects ; therapeutic use ; Colorectal Neoplasms ; drug therapy ; Humans ; Pyridines ; adverse effects ; therapeutic use ; Retrospective Studies ; Survival Analysis

Antineoplastic Agents ; adverse effects ; Consensus ; Gastrointestinal Neoplasms ; drug therapy ; Gastrointestinal Stromal Tumors ; drug therapy ; Humans ; Protein Kinase Inhibitors ; adverse effects